Multiple myeloma (MM) is a bone marrow-based malignancy of plasma cells that is diagnosed in over 30,000 patients annually in the United States. Despite the many recent advances in the treatment of MM, it remains an incurable disease. Thus, the need for the development of new effective therapies remains critical for these patients.

**Smoldering MM**
In general, it has not been shown that patients with smoldering MM (SMM) benefit from early treatment, but recent studies have identified a subset of patients who are at high-risk and may require therapy more quickly. Recent guidelines from the International Myeloma Working Group recommend immediate treatment of this subgroup of SMM. However, although findings in a Spanish study suggested that early treatment of high-risk SMM patients with the immunomodulatory agent (IMiD) lenalidomide and dexamethasone improves overall survival (OS), the design of that study limits its clinical applicability, and no other randomized trials have been completed to show the advantage of early therapy for these patients.

**Specific drugs**
The development of novel agents such as proteasome inhibitors (PIs), IMiDs, histone deacetylase inhibitors (HDACIs), and monoclonal antibodies (mAbs) in recent years has vastly changed the approach to the treatment of MM patients.

PIs that are cytotoxic to MM cells, such as bortezomib, have become a foundation for MM treatment over the past decade. However, patients develop drug resistance to bortezomib by acquiring gene mutations and through other mechanisms. In recent years, newer forms of PIs such as carfilzomib and the oral formulations ixazomib and oprozomib have been approved for use in the United States last year. Auto- and allo-transplant approaches in first remission or in relapse/refractory disease remain another mainstay of therapy, although there remains controversy around the timing of auto-transplant and perhaps the findings of a large ongoing trial in the United States will provide guidance in the future. Myeloma has gone from being a fatal disease within a few years of diagnosis to being a chronic, more manageable condition now, and perhaps a cure for many patients is not too far off.

— David H Henry, MD, FACP
been confirmed clinically in that replacement of bortezomib with carfilzomib has shown the ability to overcome resistance to bortezomib for most MM patients who receive a variety of bortezomib-containing combination treatments. A recent clinical trial has also shown improved progression-free survival (PFS) when relapsed/refractory MM (RRMM) patients are treated with carfilzomib and the steroid dexamethasone, compared with bortezomib and dexamethasone.4 Ixazomib, an oral PI, was recently approved by the US Food and Drug Administration for the treatment of previously treated MM patients.7,8 Another novel PI, oprozomib, remains in clinical development.9

The IMiD lenalidomide has been approved not only for treating RRMM patients, but for use in the front-line setting as well.10 The drug has been combined with many other active anti-MM agents, which has enhanced its efficacy.11,12 Single-arm studies have shown high response rates when lenalidomide is combined with steroids and bortezomib.13 In addition, 2 recently reported randomized trials have shown an improved PFS when lenalidomide is combined with dexamethasone and either the PI carfilzomib or ixazomib, compared with the doublet of lenalidomide and dexamethasone without 1 of the newer agents.5,11 Another IMiD, pomalidomide, has shown clinical efficacy among patients who are resistant to lenalidomide14 and is now being similarly combined with many other agents.15 Recent studies have shown high response rates when pomalidomide is combined with carfilzomib and dexamethasone in MM patients who are refractory to lenalidomide.16

In preclinical studies, the epigenetic modifying HDACis have shown both single-agent activity and enhance the anti-MM effects of many other anti-MM agents including steroids, chemotherapeutic agents, PIs, and IMiDs.27,28 Panobinostat combined with bortezomib and dexamethasone has been approved for treating RRMM patients based on an improvement in PFS from the results of a large randomized study.19 However, the drug has significant side effects, especially gastrointestinal and constitutional symptoms, which have limited its use in the clinic.

Notably, a recent retrospective analysis of nearly 300 patients treated in our clinic showed that the response rates of MM patients who are treated with lenalidomide, bortezomib, or carfilzomib-containing regimens was similar across these 3 drugs in both the front-line and salvage settings.20 Notably, the findings also showed clinical benefit (minimal response or more) in about half of the patients when the same 3 drugs are used in a second, third, or even fourth combination treatment. In addition, substantial clinical activity was observed even among patients who were refractory to the drug in a previous combination treatment. High response rates were also observed among patients who had failed treatment with either carfilzomib or bortezomib and were then treated subsequently with brtezomib or carfilzomib, respectively.

**Maintenance therapy**

There have also been many advances in the use of maintenance therapy for MM patients.21 Findings in earlier maintenance trials had shown an improvement in OS from continuing steroids such as single-agent oral prednisone at therapeutic doses for MM patients who had responded to initial therapy with steroids and chemotherapy.22 Recent study findings have suggested the benefit of other drugs as maintenance therapy for patients who completed their initial therapy.23-25 Specifically, an improvement in OS with ongoing lenalidomide alone or with dexamethasone has been demonstrated in some but not all studies.21-23 Unfortunately, studies with the PIs have not defined their role as maintenance drugs,21 but the recent availability of the oral PI ixazomib will make the performance of these studies easier to undertake.26

**Immune-based treatments**

Recently, 2 mAbs, daratumumab and elotuzumab, have become available for treating RRMM patients.26-29 Daratumumab, which targets CD38, has shown significant clinical efficacy as a single agent but nearly half of the patients who are treated with it have experienced infusion reactions leading to prolonged infusion times or discontinuation of the drug.26 Elotuzumab, which targets signaling lymphocytic activation molecule family member 7 (SLAMF7), is present on both plasma cells and natural killer (NK) cells.30 This mAb is both directly cytotoxic to MM cells while activating the NK cell population, resulting in significant anti-MM effects.30 Although the drug lacks efficacy as a single agent, it improves PFS when combined with lenalidomide and dexamethasone with very few side effects.29 Many ongoing studies are evaluating these 2 mAbs with other anti-MM agents in the RRMM setting with promising early results.31,32 Other immune-based therapies that are currently in development include targeted antibody conjugates and chimeric antigen receptor (CAR)-modified T-cell-based treatments that have been used to effectively treat other B-cell malignancies.33,34 Despite the success of CAR T-cell treatment for some patients with CD19+ B-cell lymphoma, it has been extensively evaluated preclinically only in MM. A small number of MM patients have received this cellular therapy with some suggestion of clinical benefit but, in some cases, substantial toxicity including treatment-related deaths have occurred.34,35 However, an improvement in the cytotoxic potential of CAR T-cell therapies may lead to potentially better on target-specific therapy improving clinical outcomes for the treatment of MM patients.

**Medical problems and common side effects with MM therapies**

Disease management includes not only the treatment of the disease but also other medical conditions. For instance, MM
patients with anemia often have iron or B12 deficiency unrelated to the disease.\textsuperscript{36} Drugs commonly used to treat MM such as bortezomib and lenalidomide are also responsible for the occurrence of side effects such as peripheral neuropathy. Subcutaneous instead of intravenous administration, lower doses, and changes in schedule have been shown to reduce both the incidence and severity of PN from bortezomib treatment.\textsuperscript{37-40} In addition, the severity of peripheral neuropathy among patients treated with bortezomib or thalidomide is exacerbated by a concomitantly low serum vitamin D level.\textsuperscript{41} Lenalidomide has been associated with an increased risk of developing second primary malignancies,\textsuperscript{42} although not all studies have shown this effect.\textsuperscript{43} 

**Summary**

Outcomes for MM patients are improving as a result of the recently approved new agents including mAbs. The place of these new drugs for the treatment of these patients as well as optimizing their use in combination with other effective anti-MM agents is the subject of many current clinical trials. Unfortunately, little remains known about the optimal sequencing or length of treatments for these patients; as more drugs become available, this will become even more difficult to sort out. Individualizing treatment for MM patients is also a goal for this disease so that patients can receive therapies based on the characteristics of their disease, immune system, and overall health, which should improve these patients’ length and quality of life. Most importantly, these new treatments and learning that drugs can be re-used effectively and safely in new combinations have allowed patients to have an ever increasing number of options that have resulted in dramatic improvements in the quality and length of lives of our patients with MM.

**References**


8. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRD), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the Phase 3 Tourmaline-MM1 Study (NCT01564537) [ASH abstract 717]. Blood. 2015;126.


I love treating patients with multiple myeloma because it usually means the start of a long relationship. There are several highly active agents available to treat the disease and they are often safely combined to yield even greater responses and benefits for the patient. Unfortunately, there is an almost endless number of regimens and their corresponding acronyms. In addition, the number of quality, large-volume phase 3 studies on treating multiple myeloma are limited, making it difficult to know which of the dozens of available therapies is best. Many of the treatment guidelines, such as those from the National Comprehensive Cancer Network and mSMART, rely on expert opinions to help make sense of it all.

There are also 2 somewhat divergent opinions on how best to treat myeloma. One approach is to treat it aggressively with multiple chemotherapy agents, high-dose chemotherapy followed by stem cell rescue, and prolonged maintenance also using multiple agents. The other is to treat it as an incurable, chronic disease. In latter approach one works on getting the disease under control with a combination regimen and then keeping it under control, often using a single agent to minimize toxicity. Unfortunately, we don’t know which method is best. I favor and treat patients using the latter approach because my patients tend to be older and have more comorbidities than those reported in research studies. Although I have had only a small number of patients who have gone through the more intense option, I have yet to see any cures.

When I have a newly diagnosed patient, I first determine if they even need therapy. Most patients and titin cross-reactivity of affinity-enhanced T-cells in myeloma and melanoma. Blood. 2015;122:863-871.
with smoldering myeloma can be monitored. A Spanish study that compared lenalidomide and dexamethasone with best supportive care showed a survival advantage. However, because lenalidomide was not approved for first-line myeloma in Spain, the patients in the best supportive care group never received the drug when they progressed. Therefore, the study only proved that using lenalidomide in myeloma prolongs survival. I will use lenalidomide and weekly dexamethasone (Rd) in older or frail patients, especially those with relatively minimal symptoms. If they have a response, I will drop the dexamethasone after a few months and continue lenalidomide. I will also stop both drugs entirely if I get a complete response, which helps minimize both physical and financial toxicity.

The next assessment I make at presentation is how ill the patient is. As above, an elderly woman with isolated anemia or minimal bone involvement may do very well with Rd. For patients with significant symptoms related to myeloma – hypercalcemia, significant renal dysfunction or failure, anemia, and significant bone involvement, together referred to as CRAB – my go-to regimen is cyclophosphamide, bortezomib, and dexamethasone (CyBorD). It is well tolerated, has a high rate of response, has minimal cytopenias, and is generally safe to use in the presence of renal disease. I administer bortezomib 1.3-1.5 mg/m² both subcutaneously and weekly as this has been shown to have equivalent activity with less toxicity, especially peripheral neuropathy, compared with the original biweekly intravenous administration.

I will use lenalidomide, bortezomib, and dexamethasone (RVd) if I need a more rapid response, if the patient has high-risk features such as a 17p- abnormality, or I am not
getting a satisfactory response to CyBorD. There are different variations of RVd but the one I use most is a modified version published by Rajkumar, which is a 21-day cycle of bortezomib 1.3 mg/m² on days 1, 8, and 15; lenalidomide 25 mg on days 1-14; and dexamethasone 40 mg on days 1, 8, and 15. It has a high response rate but also comes with more toxicity especially in elderly patients and patients with renal disease.

High-dose chemotherapy followed by stem-cell rescue is still considered standard therapy in patients with a good performance status but this too is being challenged in research protocols. I discuss this option with my patients and encourage an evaluation by our local transplant physicians. I still recommend it in eligible patients, especially those who would be considered at high risk of early relapse. Recently, I have had patients question the benefit of transplant. I have encouraged them to at least collect and store stem cells if they have had a good response to induction therapy.

Although data is limited, there is emerging information that continuing therapy or maintenance after reaching a maximum response or plateau phase prolongs time to next therapy. If I start a patient on CyBorD and they are not going for transplant, I drop the cyclophosphamide and dexamethasone once they have reached a plateau. I continue the bortezomib but with fewer injections, such as 3 weeks on and 1 week off or every other week. I also sometimes drop the dose from 1.3 mg/m² to 1 mg/m², especially if they are showing signs of peripheral neuropathy. If the patient undergoes high-dose chemotherapy followed by stem-cell rescue, I typically recommend maintenance lenalidomide 10 mg per day, but I discuss the potential risks involved including secondary hematologic malignancies and cytopenias.

Second-line therapy and beyond has become much more complex and many of my choices are dependent on how the patient is progressing, what he or she was already taking, and what toxicities are being experienced. If the patient was on lenalidomide, then I generally have gone to CyBorD similar to the induction regimen. If the patient was on bortezomib alone and adding cyclophosphamide and dexamethasone as in CyBorD was ineffective, I would often try to add another drug to bortezomib such as liposomal doxorubicin. However, the mixing of a proteasome inhibitor, such as carfilzomib or ixazomib, with an immunomodulator, such as lenalidomide or pomalidomide, is very compelling. Carfilzomib, lenalidomide, and dexamethasone (KRd) had a high response rate of 73% and progression-free survival of 26.3 months in patients who had 1-3 previous therapies and did not immediately progress on lenalidomide just prior to entering the study. This is a 28-day regimen, with carfilzomib given at 27 mg/m² on days 1, 2, 8, 9, 15, and 16 with a starting dose of 20 mg/m² for days 1 and 2 of the first cycle only. Lenalidomide was given at 25 mg on days 1-21 and dexamethasone was 40 mg on days 1, 8, 15, and 22. In my experience, this regimen is very active but needs to be monitored closely because it also causes significant fatigue and low blood counts especially in the elderly. If I am going to use it in a patient who may be on the edge of fraility, I will lower the dose of lenalidomide to 10-15 mg daily. We are starting to get some clarity, but it has taken several years since carfilzomib was approved to better understand the best dose, schedule, and combinations. Because there is activity in weekly dosing, I have reduced it to weekly for patients who are not tolerating the standard biweekly and, if they are doing well, I try to increase the individual dose.

Panobinostat, a histone deacetylase inhibitor, along with bortezomib and dexamethasone was approved last year in patients who have received previous bortezomib and an immunomodulating therapy. The combination has 25% grade 3/4 risk of diarrhea, which has me and my patients reluctant to try it. Ixazomib, an oral proteasome inhibitor, and elotuzumab, a SLAMF7 monoclonal antibody, each given along with lenalidomide and dexamethasone were both approved last year in patients who have received 1-3 previous treatments. Both regimens were shown to be superior to lenalidomide and dexamethasone alone, however, there is no information as to whether either of those is better than RVd or KRd. In addition, there is limited data on single-agent ixazomib, and monotherapy with elotuzumab does not seem to be active.

Daratumumab has single-agent activity in patients who have progressed on both a proteasome inhibitor and lenalidomide. There are concerns regarding reactions leading to prolonged infusions, especially with the first dose, but most of these are mild. Because of the first-week reactions, a potentially long infusion time, and its relatively short shelf life, it is difficult to give it per the package insert in the outpatient setting. Working with many members in our group, we developed our own regimen, splitting the infusion over 2 days for the first week only. This is not in accordance with the package insert but thus far seems to be working well. This has also allowed us to keep our patients in the clinic rather than sending them to the hospital. The most common problem I have had with the drug has been primarily related to the significant amount of steroids recommended. Daratumumab can also bind to CD38 present on red blood cells and can interfere with serologic testing because of a false positive Coombs test. It also masks antibody detection to minor antigens in the patient’s serum. If the patient requires a blood transfusion, your blood bank needs to be notified that the patient received daratumumab.

Myeloma is a complex family of diseases that cannot be treated by a simple “cookbook” approach. This is why I find treating this disease both challenging and stimulating. Although cures are rare, the newer and highly effective...
therapies are allowing more patients to live with their disease for years, some past a decade. They also give me hope that I will see more complete responses in my patients. None of these advancements would have been possible without the participation of hundreds of patients on clinical trials, and I encourage you to help continue these advancements by enrolling your patients in clinical trials when they are available.

References